| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,000,000 ) |
| | 2025 | 2025 | OSSIUM HEALTH, INC. | 80 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R44AI183961 | Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | 001 | 2 | NIH | 9/2/2025 | $1,000,000 |
| | 2025 | 2024 | OSSIUM HEALTH, INC. | 80 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R44AI183961 | Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | 000 | 1 | NIH | 11/20/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $123,392 ) |
| | 2024 | 2024 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R44AI183961 | Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | 000 | 1 | NIH | 8/14/2024 | $375,113 |
| | 2024 | 2022 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 000 | 5 | NIH | 3/25/2024 | $0 |
| | 2024 | 2022 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 001 | 5 | NIH | 4/8/2024 | -$140,369 |
| | 2024 | 2021 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R41GM140787 | Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media | 000 | 1 | NIH | 3/13/2024 | -$111,352 |
| | 2024 | 2021 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R43AI155196 | A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance | 000 | 2 | NIH | 3/27/2024 | $0 |
| | 2024 | 2021 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R44HL142418 | Novel strategies for storage and recovery of cadaveric bone marrow stem cells | 000 | 3 | NIH | 12/6/2023 | $0 |
| | 2024 | 2021 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R41HL155004 | A novel approach to Mesenchymal Stem Cell Transduction | 000 | 1 | NIH | 4/16/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$24,540 ) |
| | 2023 | 2021 | OSSIUM HEALTH INC | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R41HL155004 | A novel approach to Mesenchymal Stem Cell Transduction | 000 | 1 | NIH | 3/28/2023 | $0 |
| | 2023 | 2020 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R44AI129444 | Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone Marrow | 000 | 3 | NIH | 7/27/2023 | -$24,540 |
|
| Issue Date FY: 2022 ( Subtotal = $572,754 ) |
| | 2022 | 2022 | OSSIUM HEALTH, INC. | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 000 | 5 | NIH | 6/15/2022 | $572,754 |
| | 2022 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R41GM140787 | Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media | 000 | 1 | NIH | 11/3/2021 | $0 |
| | 2022 | 2020 | OSSIUM HEALTH INC | 78 TEHAMA ST | SAN FRANCISCO | CA | 94105-3110 | SAN FRANCISCO | USA | R43AI155197 | Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | 000 | 1 | NIH | 1/28/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,299,912 ) |
| | 2021 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R41HL155004 | A novel approach to Mesenchymal Stem Cell Transduction | 000 | 1 | NIH | 9/20/2021 | $248,452 |
| | 2021 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R44HL142418 | Novel strategies for storage and recovery of cadaveric bone marrow stem cells | 001 | 3 | NIH | 2/17/2021 | $687,302 |
| | 2021 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R41GM140787 | Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of media | 000 | 1 | NIH | 9/20/2021 | $224,453 |
| | 2021 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 001 | 4 | NIH | 4/13/2021 | $571,665 |
| | 2021 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 002 | 4 | NIH | 8/26/2021 | $357,014 |
| | 2021 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R43AI155196 | A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance | 000 | 2 | NIH | 6/28/2021 | $142,485 |
| | 2021 | 2021 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 000 | 3 | NIH | 12/29/2020 | $68,541 |
| | 2021 | 2020 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R44HL142418 | Novel strategies for storage and recovery of cadaveric bone marrow stem cells | 000 | 2 | NIH | 10/26/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,866,390 ) |
| | 2020 | 2020 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | R44AI129444 | Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone Marrow | 001 | 3 | NIH | 4/28/2020 | $999,998 |
| | 2020 | 2020 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | R43AI155196 | A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance | 000 | 1 | NIH | 7/8/2020 | $157,465 |
| | 2020 | 2020 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 003 | 3 | NIH | 8/20/2020 | $32,089 |
| | 2020 | 2020 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 001 | 3 | NIH | 5/20/2020 | $462,874 |
| | 2020 | 2020 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | R44HL142418 | Novel strategies for storage and recovery of cadaveric bone marrow stem cells | 000 | 2 | NIH | 2/28/2020 | $778,661 |
| | 2020 | 2020 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R43AI155197 | Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury | 000 | 1 | NIH | 8/18/2020 | $299,998 |
| | 2020 | 2019 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 002 | 2 | NIH | 5/21/2020 | $87,984 |
| | 2020 | 2019 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R44AI129444 | Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone Marrow | 000 | 2 | NIH | 11/29/2019 | $17,974 |
| | 2020 | 2018 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 000 | 1 | NIH | 5/20/2020 | $47,321 |
| | 2020 | 2017 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R43AI129444 | Deceased Donor Bone Marrow Salvage and Processing | 000 | 1 | NIH | 11/29/2019 | -$17,974 |
| | 2020 | 2017 | OSSIUM HEALTH, INC. | 1121 HOWARD ST | SAN FRANCISCO | CA | 94103-3921 | SAN FRANCISCO | USA | R43HL139315 | Novel Disaccharide-Based Cryopreservation Approach for Stable, -80?C Storage of Stem Cells | 000 | 1 | NIH | 2/15/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,185,181 ) |
| | 2019 | 2019 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 001 | 2 | NIH | 8/22/2019 | $199,653 |
| | 2019 | 2019 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 000 | 2 | NIH | 4/10/2019 | $313,587 |
| | 2019 | 2019 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | R44AI129444 | Optimizing Industrial-Scale GMP Processes for Recovering and Banking Deceased Donor Bone Marrow | 000 | 2 | NIH | 5/7/2019 | $682,556 |
| | 2019 | 2018 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | R43HL142418 | Novel strategies for storage and recovery of cadaveric bone marrow stem cells | 000 | 1 | NIH | 9/23/2019 | -$10,615 |
| | 2019 | 2017 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | R43HL139315 | Novel Disaccharide-Based Cryopreservation Approach for Stable, -80?C Storage of Stem Cells | 000 | 1 | NIH | 11/8/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $501,000 ) |
| | 2018 | 2018 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | R43HL142418 | Novel strategies for storage and recovery of cadaveric bone marrow stem cells | 000 | 1 | NIH | 3/8/2018 | $224,961 |
| | 2018 | 2018 | OSSIUM HEALTH, INC. | 25 TAYLOR ST | SAN FRANCISCO | CA | 94102-3916 | SAN FRANCISCO | USA | U01AI138334 | OssioStem-matched multipotent MSC (M3): banked, low passage bone marrow MSC for treatment of hematopoietic acute radiation syndrome. | 000 | 1 | NIH | 4/19/2018 | $276,039 |
|
| Issue Date FY: 2017 ( Subtotal = $511,667 ) (Continued on the next page) |
| | 2017 | 2017 | OSSIUM HEALTH, INC. | 151 10TH ST | SAN FRANCISCO | CA | 94103-2604 | SAN FRANCISCO | USA | R43AI129444 | Deceased Donor Bone Marrow Salvage and Processing | 000 | 1 | NIH | 2/2/2017 | $272,587 |
|
